SEGMENT INFORMATION (Tables)

9 Months Ended

Sep. 30, 2020

Segment Reporting [Abstract]

Information About Reportable Segments and Reconciliation of Segment Net Sales to Consolidated Net Sales and Segment Pre-Tax Income to Consolidated Pre-Tax Income

The table below presents information about Edwards Lifesciences' reportable segments (in millions):

	Three Months Ended    September 30,				Nine Months Ended    September 30,
	2020		2019		2020		2019
Segment Net Sales
United States	$	662.0	$	647.8	$	1,845.6	$	1,835.5
Europe	241.5		219.8		695.9		684.3
Japan	109.9		110.0		325.0		322.9
Rest of World	115.2		112.0		323.4		316.5
Total segment net sales	$	1,128.6	$	1,089.6	$	3,189.9	$	3,159.2
Segment Operating Income
United States	$	453.8	$	447.4	$	1,264.0	$	1,258.3
Europe	124.2		111.5		356.2		353.2
Japan	69.2		70.7		209.9		202.8
Rest of World	35.6		36.7		105.2		99.8
Total segment operating income	$	682.8	$	666.3	$	1,935.3	$	1,914.1

The table below presents reconciliations of segment net sales to consolidated net sales and segment operating income to consolidated pre-tax income (in millions):

	Three Months Ended    September 30,						Nine Months Ended    September 30,
	2020			2019			2020			2019
Net Sales Reconciliation
Segment net sales	$	1,128.6		$	1,089.6		$	3,189.9		$	3,159.2
Foreign currency	12.3			4.4			4.7			14.7
Consolidated net sales	$	1,140.9		$	1,094.0		$	3,194.6		$	3,173.9
Pre-tax Income Reconciliation
Segment operating income	$	682.8		$	666.3		$	1,935.3		$	1,914.1
Unallocated amounts:
Corporate items	(331.9		)	(384.2		)	(1,005.6		)	(1,073.1		)
Special charge (Note 4)	—			—			—			(24.0		)
Intellectual property litigation expenses	(8.4		)	(7.9		)	(400.8		)	(19.5		)
Change in fair value of contingent consideration liabilities, net	9.0			2.3			(8.4		)	(12.4		)
Foreign currency	6.3			17.8			25.7			50.9
Consolidated operating income	357.8			294.3			546.2			836.0
Non-operating income	6.5			7.4			14.4			15.0
Consolidated pre-tax income	$	364.3		$	301.7		$	560.6		$	851.0

Enterprise-Wide Information

nterprise-wide information is based on actual foreign exchange rates used in the Company's consolidated condensed financial statements.

	Three Months Ended    September 30,				Nine Months Ended    September 30,
	2020		2019		2020		2019
	(in millions)
Net Sales by Geographic Area
United States	$	662.0	$	647.8	$	1,845.6	$	1,835.5
Europe	253.8		222.6		707.8		699.0
Japan	113.9		112.9		330.7		324.4
Rest of World	111.2		110.7		310.5		315.0
	$	1,140.9	$	1,094.0	$	3,194.6	$	3,173.9
Net Sales by Major Product Group
Transcatheter Aortic Valve Replacement	$	744.6	$	700.0	$	2,081.1	$	1,975.4
Transcatheter Mitral and Tricuspid Therapies	12.1		9.7		28.7		21.0
Surgical Structural Heart	203.3		204.1		557.6		636.6
Critical Care	180.9		180.2		527.2		540.9
	$	1,140.9	$	1,094.0	$	3,194.6	$	3,173.9

	September 30, 2020		December 31, 2019
	(in millions)
Long-lived Tangible Assets by Geographic Area
United States	$	1,031.9	$	849.1
Europe	159.1		101.5
Japan	18.6		21.7
Rest of World	293.3		269.4
	$	1,502.9	$	1,241.7